Copilot About Resources Open Copilot
Oncology Intelligence

Clinical intelligence
built for where you
actually practice.

An oncology AI agent that adapts to your country — your guidelines, your regulators, your reimbursement reality. Ask anything. Get a locally accurate, GRADE-graded answer.

Open Copilot See it in action

The same question. Two countries. Two different answers.

"Is olaparib available for my patient
with BRCA-mutated ovarian cancer?"

🇵🇹 Portugal
Evidence
⊕⊕⊕⊕ High certainty
Olaparib significantly improves PFS in BRCA1/2-mutated advanced ovarian cancer. SOLO-1 (1L maintenance): PFS 56.0 vs 13.8 months (HR 0.33). SOLO-2 (2L+): PFS 19.1 vs 5.5 months (HR 0.30).
ESMO Grade A · Level I SOLO-1 SOLO-2
Regulatory & reimbursement
EMA authorised for BRCA-mutated advanced ovarian cancer, 1L maintenance and platinum-sensitive relapsed. INFARMED reimbursement granted under Autorização de Utilização Especial (AUE). SNS covered for confirmed BRCA1/2 pathogenic variants — prior platinum-based chemotherapy required.
Recruiting trials in Portugal
2 open studies matching BRCA-mutated ovarian cancer found in EU CTR with Portuguese sites. Confirm eligibility with site coordinator.
EU CTR EudraCT
🇧🇷 Brazil
Evidence
⊕⊕⊕⊕ High certainty
Same evidence base applies globally. SOLO-1 and SOLO-2 are the pivotal trials. ASCO and ESMO both issue Grade A recommendations for BRCA-mutated ovarian cancer.
ASCO Grade A SOLO-1 SOLO-2
Regulatory & reimbursement
ANVISA approved (Lynparza®) for BRCA-mutated advanced ovarian cancer, 1L maintenance and relapsed platinum-sensitive disease. CONITEC has not issued a public reimbursement recommendation for this indication as of last review. Access currently via private health plans or patient assistance programmes. Confirm current SUS status.
Recruiting trials in Brazil
Studies available on ClinicalTrials.gov with Brazilian sites for BRCA-mutated ovarian cancer — primarily industry-sponsored Phase III combinations. Confirm eligibility with site coordinator.
ClinicalTrials.gov Brazil sites

Example query. Clinical data, regulatory status and reimbursement conditions are subject to change.

How it works

Three things.
One agent.

01

Evidence synthesis

PubMed, Cochrane and the oncology-specific guidelines for your region — synthesised into a GRADE-graded answer, not a list of links. Certainty of evidence made explicit every time.

PubMed Cochrane ESMO · ASCO · NCCN
02

Trial finder

ClinicalTrials.gov, EU CTR and EudraCT unified in one query. Filtered by your country, tumour type, line of therapy and biomarker. Site-level status — not just whether the trial exists.

ClinicalTrials.gov EU CTR EudraCT
03

Local context

Approval status, reimbursement decisions and formulary conditions for your country — automatically. The agent knows the difference between INFARMED, CADTH, ANVISA and G-BA without being asked.

EMA · FDA · Health Canada · ANVISA Reimbursement-aware
Where it works

Your country.
Your context.

🇵🇹Portugal
ApprovalEMA · INFARMED
ReimbursementAUE pathway · SNS
GuidelinesESMO CPG
TrialsEU CTR · EudraCT
🇧🇷Brazil
ApprovalANVISA
ReimbursementCONITEC · SUS
GuidelinesASCO · ESMO · SBOC
TrialsClinicalTrials.gov
🇨🇦Canada
ApprovalHealth Canada
ReimbursementCADTH · PCODR
GuidelinesASCO · NCCN · CAO
TrialsClinicalTrials.gov
🇩🇪Germany
ApprovalEMA · G-BA · IQWiG
ReimbursementG-BA benefit assessment
GuidelinesESMO · AWMF · DKG
TrialsEU CTR · EudraCT
🇫🇷France
ApprovalEMA · ANSM
ReimbursementHAS · AAP (Accès Précoce)
GuidelinesESMO · INCa
TrialsEU CTR · EudraCT
🌍 More comingSoon
NextUK · Spain · Italy · Australia
ThenMexico · Colombia · Argentina
Contacthello@silvercancer.com

Ask it
where
you are.

Open the Copilot, tell it your country, and ask your first clinical question. The answer will tell you more than this page.

Open Copilot About us

No patient data required · GDPR compliant